HPRA Completes Audit of Biocon Biologics New mAbs Drug Substance Facility in Bengaluru

Biocon Biologics Spokesperson has announced that the Health Products Regulatory Authority (HPRA), Ireland, conducted a GMP inspection of one of Biocon Biologics' new monoclonal antibody drug substance manufacturing facilities in Biocon Park, Bengaluru, India, between March 28 and April 1, 2022.

The inspection report contains no 'critical' observations and only one of the deficiencies is categorized as 'major' which is being addressed expeditiously in consultation with the regulatory agency. This facility will help us address the additional requirements of our products in EU market.

Shares of Biocon Limited was last trading in BSE at Rs. 372.65 as compared to the previous close of Rs. 368.45. The total number of shares traded during the day was 502154 in over 2832 trades.

The stock hit an intraday high of Rs. 377.30 and intraday low of 361.75. The net turnover during the day was Rs. 186618076.00.

Source : Equity Bulls

Keywords

Biocon INE376G01013 BioconBiologics HPRA Ireland GMPInspection